跳至主要内容
临床试验/NCT03683511
NCT03683511已完成不适用

Population Pharmacokinetics Modeling : a Priori Optimization of Amikacin First Dose in Critically Ill Patients Using a Nomogram

Nantes University Hospital1 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2014年4月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
138
试验地点
1
主要终点
amikacin infusion

研究概览

简要总结

The aim of this study is to elaborate nomograms to optimize amikacine first dosing in critically ill patients, using a population pharmacokinetics model elaborated with multicentric data.

详细描述

French guidelines recommend for probabilistic therapy to reach an amikacin concentration 1 hour after beginning the infusion ≥ 60 mg/L. This target is rarely achieved in the ICU despite a 30 mg/kg recommended dosage. Using data collected prospectively in critically ill patients of Nîmes (France) (1) and Nantes (France), we will elaborate a population pharmacokinetic model on the non-parametric software Pmetrics and on the parametric software Monolix. We will calculate probability of target attainment of Monte-Carlo simulations, using the non-parametric model. Nomograms to determine optimal first dose of amikacin in critically ill patients, according to a few variables previously identified, will be produced.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients treated with amikacin for sepsis in one of the participating ICU will be included.

排除标准

  • patients with aminoglycoside allergy, history of myasthenia, pregnancy, under guardianship.

结局指标

主要结局

amikacin infusion

时间窗: one hour after beginning of infusion.ed

Target is defined as 8 times x Minimal Inhibatory Concentration for MIC = 4 mg/L and MIC = 8 mg/L. Those PTA will be calculated using the final pharmacokinetics model, according to the dependent variables.

次要结局

  • maximal dose of amikacin (in mg) allowed to have a probability of target attainment (PTA) of 50% or less for the trough concentration.(24 hours after beginning of infusion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验